Previsioni

Il prezzo obiettivo medio degli analisti è +11,18€ (+33,73%). La mediana è +10,09€ (+20,69%).

Acquista	6
Mantieni	3
Vendi	0

Notizie Vai al feed delle notizie

Curaleaf to implement 1-for-3 reverse split effective June 5

Curaleaf has announced a 1-for-3 reverse stock split to be effective on or about June 5, 2026, intended to meet U.S. exchange minimum price requirements and enable a potential uplisting. The move will reduce outstanding common shares from 698,728,008 to approximately 232,909,336 and will proportionally adjust options and convertible instruments. The stock will continue trading under the ticker CURA on the Toronto Stock Exchange; the company reports a market capitalization of about $2.7 billion and trailing twelve‑month revenue of $1.29 billion. Analyst price targets cited in the report range from $3.86 to $4.77. » Altro su de.investing.com
Curaleaf appoints Torsten Greif of Four 20 Pharma to the board of directors

Curaleaf has appointed Torsten Greif, co-founder of Four 20 Pharma, to its board of directors. Four 20 Pharma, in which Curaleaf holds a majority stake, is a German cannabis producer with EU-GMP and GDP licences. Curaleaf intends to use Greif’s local expertise to advance the expansion of its European activities and the supply of EU-GMP‑certified medical cannabis to Germany and other markets. » Altro su de.investing.com
Curaleaf opens fifth dispensary in Ohio and expands US retail to 162 locations

Curaleaf has opened a new dispensary in Findlay, Ohio, increasing its presence in the state to five locations. The site offers cannabis products to medical patients and recreational customers, including the brands Select BRIQ, Find and Grassroots. In total, Curaleaf now operates 162 retail stores in the U.S. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Curaleaf Holdings Inc. ha registrato ricavi pari a 295.04m€ e un utile netto di 10.94m€

(EUR)	giu 2026	YoY
Ricavi	+295.04m	8,77%
Utile lordo	+148.88m	47,58%
Utile netto	+10.94m	123,86%
EBITDA	+19.56m	63,28%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+2.15b€
Numero di azioni	264.23m
Massimo/minimo a 52 settimane	+13,01€ - +4,64€
Dividendi	No
Beta	1,63
Rapporto P/E	−69,10
Rapporto PEG	−0,44
Rapporto P/B	+2,87
Rapporto P/S	+1,91

Profilo aziendale

Curaleaf Holdings, Inc. betreibt ein Cannabisunternehmen in den Vereinigten Staaten. Das Unternehmen ist in zwei Segmenten tätig: Cannabis Operations und Non-Cannabis Operations. Das Segment Cannabis Operations beschäftigt sich mit der Produktion und dem Verkauf von Cannabis über Einzel- und Großhandelskanäle. Das Segment Non-Cannabis Operations bietet professionelle Dienstleistungen an, einschließlich Anbau, Verarbeitung und Einzelhandels-Know-how sowie Back-Office-Verwaltung, Lizenzierung von geistigem Eigentum, Immobilienleasing und Kreditvergabe an Lizenznehmer von medizinischem Cannabis und Cannabis für den Erwachsenengebrauch im Rahmen von Management-Service-Vereinbarungen. Das Unternehmen bietet Blüten, Pre-Rolls, Flower-Pods und Verdampferkartuschen mit Trockenkräutern, Konzentrate zum Verdampfen, wie vorgefüllte Verdampferkartuschen und Einwegverdampferstifte, sowie Konzentrate zum Dabben, einschließlich Destillat-Tropfen, Minzbonbons, topische Balsame und Lotionen, Tinkturen, Lutschtabletten, Kapseln und Esswaren. Das Unternehmen bietet auch hanfbasierte CBD-Produkte an. Mit Stand vom 16. Juni 2022 betrieb es 134 Apotheken und 26 Anbauflächen in 22 Bundesstaaten der Vereinigten Staaten. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Wakefield, Massachusetts.

Nome	Curaleaf Holdings Inc.
CEO	Boris Alexis Jordan
Sede centrale	Stamford, ct Stati Uniti
Sito web	curaleaf.com
Settore	Beni di prima necessità
Industria	Prodotti per la cura della persona
Quotazione in borsa	29/10/2018
Dipendenti	5.554